U.S. Inhalation Anesthesia Market Size, Share & Trends Analysis Report By Drug (Sevoflurane, Desflurane), By Application (Induction, Maintenance), By End Use (Hospitals, ASC), And Segment Forecasts
Published Date: May - 2025 | Publisher: MIR | No of Pages: 260 | Industry: healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2999 Download Sample Ask for Discount Request CustomizationU.S. Inhalation Anesthesia Market Trends
The size of the U.S. inhalation anesthesia market was estimated at USD 743.8 million in 2024 and is anticipated to rise at a CAGR of 6.1% during 2025-2030. The growth in the market is driven by the growing number of surgical operations and the escalation in shorter hospital stays demand. Inhalation anesthesia produces a reversible unconscious state with loss of sensation, thus facilitating pain-free surgeries. It is basically administered for routine anesthesia in operations, especially in outpatients, pediatrics, and needle-phobic patients. Moreover, inhalation anesthetics are beneficial in diagnostic tests and may be utilized outside the operating room for ICU sedation or status asthmaticus. Agents like nitrous oxide are also used to offer moderate to minimal sedation in dentistry.
The National Library of Medicine cited that between 40 to 50 million major surgeries are done each year in the U.S. Inhalation anesthesia is important in cancer biopsies and diagnosis, keeping patients comfortable throughout the process. Based on estimates from the National Cancer Institute, the U.S. is expected to experience about 2,001,140 new cases of cancer diagnosed in 2024. Of these cases, about 14,910 children and adolescents between the ages of 0 and 19 will be diagnosed with cancer. This increasing prevalence of cancer will certainly drive up demand for the U.S. inhalation anesthesia market, which underscores its significance in pediatric and adult oncology treatment.
Sedation is also used extensively in dental surgery to provide comfort to the patient. The top three most common dental surgeries performed in Los Angeles are wisdom tooth removal, root canal, and dental implant surgery. Cedars-Sinai, a non-profit teaching hospital and academic medical center in Los Angeles, conducts approximately 32,000 operations per year through its 42 operating rooms. This high rate of surgeries makes the value of proper sedation methods in improving patient experience during dental treatments even more important, thereby augmenting the need for the U.S. inhalation anesthesia sector.
Report Coverage & Deliverables
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Drug Insights
The sevoflurane product was the market leader in the U.S. inhalation anesthesia market with the highest revenue share of 75.5% in 2024. Sevoflurane is a fluorinated ether anesthetic with a sweet odor and rapid onset and recovery of action, which is ideal for both induction and maintenance of anesthesia. It has become extremely popular in day surgery with rapid achievement of deep anesthesia and short recovery periods. More than 900,000 cardiac operations, such as coronary bypass grafting, are performed annually in the U.S., further enhancing the need for the drug sevoflurane since it is used more and more in cardiac surgery because of its beneficial hemodynamic properties and cardio-protective action. Notably, it is not irritating to the respiratory tract, reducing complications like coughing or breath-holding on induction.
The isoflurane drug is anticipated to register a high CAGR of 4.6% during the forecast period. Isoflurane is a non-specific inhalation anesthetic for induction and maintenance of anesthesia, inducing muscle relaxation and diminishing pain sensitivity by modifying tissue excitability. It is commonly used in cardiac, thoracic, and neurosurgical operations and general surgical practice. The growth in these procedures has fueled demand for this drug in the U.S. inhalation anesthesia market. In the United States, cardiothoracic surgeons conduct about 530,000 general thoracic operations each year, and 33,483 neurosurgical procedures were conducted between 2012 and 2022.
Application Insights
The maintenance phase captured the highest revenue market share in the U.S. inhalation anesthesia market in 2024. Increased surgical volumes propel the segment growth, technological advancements in anesthetic delivery systems, and increased use of inhaled anesthetics as opposed to intravenous due to prolonged sedation. The phase provides patient stability during complex procedures such as abdominal, spine, hernia repair, brain, and knee surgeries. Top U.S. spine surgery centers like Emory University Hospital, UCSF Medical Center, Och Spine Hospital, and Brigham and Women's Hospital indicate the trend. Interestingly, more than 1 million hernia repairs are conducted each year, as per the U.S. Food and Drug Administration (FDA) in the U.S.
The induction phase will increase at a high CAGR during the forecast period. The increasing popularity of the use of inhalation anesthesia in the induction stage of surgery is spurred on by infants and young children. Some of the most common surgeries using inhalation anesthesia in children include correction for congenital heart defects, neurological disorders, airway obstruction, and gastrointestinal anomalies. In the United States, almost 1 out of 100 newborns, about 40,000 annually, have a heart defect. Besides, acute gastroenteritis is still a major issue, resulting in roughly 1.5 million doctor visits, 200,000 admissions to the hospital, and 300 deaths of children each year, increasing the use of inhalation anesthesia during induction all the more.
End Use Insights
The hospitals dominated the U.S. inhalation anesthesia market with the highest revenue share in 2024. A significant driver is the extensive application of inhalation anesthesia in surgical procedures and intensive care unit (ICU) sedation, wherein anesthetic gases or volatile liquids are administered via breathing masks, laryngeal mask airways, or tracheal tubes. Further, the increasing incidence of motor vehicle accidents considerably contributes to this demand. In 2022, there were more than 2.6 million emergency department visits related to motor vehicle accident injuries, many of which involved surgical procedures with anesthesia. In addition, nearly 869,000 cervical spine injuries due to traffic crashes are incurred annually, many of which involve the need for the use of inhalation anesthesia for treatment and surgery.
The Ambulatory Surgical Centers (ASC) segment is anticipated to expand at the highest CAGR during the forecast period. The rising number of surgeries is propelling the surge in demand for inhalation anesthesia in ASCs. As reported by the Hoag Review, more than 190 ASCs in the United States conducted minimally invasive spine procedures in February 2022, showing notable growth. Typical procedures in ASCs are orthopedics, ophthalmology, gastroenterology, ENT, cosmetic procedures, urology, gynecology, and podiatry. With more than 27,000 practicing orthopedic surgeons in the U.S. by 2023, including spine and pediatric specialists, orthopedics continues to be one of the most in-demand specialties in the U.S. Orthopedics continues to be one of the most in-demand and high-demand medical specialties, according to the American Board of Orthopedic Surgery.
Key U.S. Inhalation Anesthesia Company Insights
Some of the key players in the U.S. inhalation anesthesia market are Baxter; AbbVie Inc.; and Piramal Enterprises Ltd. These organizations constantly develop safer, more effective anesthetic agents, advance delivery systems, and meet regulatory requirements. They also emphasize patient outcome improvement, diversification of their product portfolios, and responsiveness to increasing surgical and critical care needs in diverse healthcare environments.
Baxter is a health care business that markets a variety of anesthesia products, including inhalation anesthetics. They concentrate on delivering advanced perioperative solutions that are designed with safety, efficiency, and enhanced patient results in mind. Baxter's products enable routine procedures and critical care in many health care environments.
AbbVie Inc. is a biopharmaceutical organization that distributes inhalation anesthetics, such as sevoflurane, under the Ultane brand name. It focuses on safety and efficiency when delivering anesthesia and assists healthcare professionals with detailed product information and compatibility with vaporizers.
Key U.S. Inhalation Anesthesia Companies
- Baxter
- AbbVie Inc.
- Piramal Enterprises Ltd.
- Hikma Pharmaceuticals PLC
- Halocarbon, LLC
- Sandoz Group AG
- Fresenius Kabi AG
Recent Developments
- In August 2024, OhioHealth became the first health system in central Ohio to eliminate desflurane, a potent greenhouse gas used in anesthesia, replacing it with the more environmentally friendly sevoflurane.
U.S. Inhalation Anesthesia Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 788.5 million |
|
Revenue forecast in 2030 |
USD 1.06 billion |
|
Growth rate |
CAGR of 6.1% from 2025 to 2030 |
|
Base year for estimation |
2024 |
|
Historical data |
2018 - 2023 |
|
Forecast period |
2025 - 2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Drug, application, end use |
|
Country scope |
U.S. |
|
Key companies profiled |
Baxter; AbbVie Inc.; Piramal Enterprises Ltd.; Hikma Pharmaceuticals PLC; Halocarbon, LLC; Sandoz Group AG; Fresenius Kabi AG |
|
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
|
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
U.S. Inhalation Anesthesia Market Report Segmentation
Drug Outlook (Revenue, USD Million, 2018 - 2030)
-
-
Sevoflurane
-
Desflurane
-
Isoflurane
-
Others
-
-
Application Outlook (Revenue, USD Million, 2018 - 2030)
-
Induction
-
Maintenance
-
-
End Use Outlook (Revenue, USD Million, 2018 - 2030)
-
Hospitals
-
Ambulatory Surgical Centers (ASC)
-
Others
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy